

NCT03350815 Raw comparison:

Summary:
CHIA has 20 criteria while your personal folder has 23 criteria
Total found criteria: 19/20
Total not Found: 1/20
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Understand and communicate with the investigator   │ Understand and communicate with the investigator   │
│ comply with the requirements of the study and give │ comply with the requirements of the study and give │
│ a written signed and dated informed consent        │ a written signed and dated informed consent        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or non-pregnant non-lactating female patients │ Male or non-pregnant non-lactating female patients │
│ at least 18 years of age                           │ at least 18 years of age                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of moderate to severe Ankylosing         │ Diagnosis of moderate to severe Ankylosing         │
│ Spondylitis (AS) with prior documented radiologic  │ Spondylitis (AS) with prior documented radiologic  │
│ evidence fulfilling the Modified New York criteria │ evidence fulfilling the Modified New York criteria │
│ for AS                                             │ for AS                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active AS assessed by total Bath Ankylosing        │ Active AS assessed by total Bath Ankylosing        │
│ Spondylitis Disease Activity index (BASDAI) = 4    │ Spondylitis Disease Activity index (BASDAI) ≥ 4    │
│ (0-10) at baseline                                 │ (0-10) at baseline                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Spinal pain as measured by BASDAI question #2 = 4  │ Spinal pain as measured by BASDAI question #2 ≥ 4  │
│ cm (0-10 cm) at baseline                           │ cm (0-10 cm) at baseline                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total back pain as measured by visual analog scale │ Total back pain as measured by visual analog scale │
│ (VAS) = 40 mm (0-100 mm) at baseline               │ (VAS) ≥ 40 mm (0-100 mm) at baseline               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients should have been on non-steroidal anti-   │ Patients should have been on non-steroidal anti-   │
│ inflammatory drugs (NSAIDs) at the maximum         │ inflammatory drugs (NSAIDs) at the maximum         │
│ tolerated dose for at least 4 weeks prior to their │ tolerated dose for at least 4 weeks prior to their │
│ Baseline Visit with an inadequate response or for  │ Baseline Visit with an inadequate response or for  │
│ less than 4 weeks if withdrawn for intolerance     │ less than 4 weeks if withdrawn for intolerance     │
│ toxicity or contraindications                      │ toxicity or contraindications                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stable dose of NSAIDs including Cyclooxygenase-1   │ Stable dose of NSAIDs including Cyclooxygenase-1   │
│ (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for │ (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for │
│ at least 2 weeks before their Baseline Visit       │ at least 2 weeks before their Baseline Visit       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have been on a tumor necrosis factor  │ Patients who have been on a tumor necrosis factor  │
│ alpha (TNFa) inhibitor (not more than one) must    │ alpha (TNFα) inhibitor (not more than one) must    │
│ have experienced an inadequate response to         │ have experienced an inadequate response to         │
│ previous or current treatment given at an approved │ previous or current treatment given at an approved │
│ dose for at least 3 months prior to baseline or    │ dose for at least 3 months prior to baseline or    │
│ had been intolerant upon administration of an      │ had been intolerant upon administration of an      │
│ anti-TNFa agent                                    │ anti-TNFα agent                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total ankylosis of the spine                       │ Total ankylosis of the spine                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of other investigational drugs within 5 half-  │ Use of other investigational drugs within 5 half-  │
│ lives of enrollment or within 4 weeks before the   │ lives of enrollment or within 4 weeks before the   │
│ Baseline Visit whichever is longer                 │ Baseline Visit whichever is longer                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypersensitivity to any of the study    │ History of hypersensitivity to any of the study    │
│ drugs or its excipients or to drugs of similar     │ drugs or its excipients or to drugs of similar     │
│ chemical classes                                   │ chemical classes                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chest x-ray computerized tomography (CT) scan or   │ Chest x-ray computerized tomography (CT) scan or   │
│ chest magnetic resonance imaging (MRI) with        │ chest magnetic resonance imaging (MRI) with        │
│ evidence of ongoing infectious or malignant        │ evidence of ongoing infectious or malignant        │
│ process obtained within 3 months prior to          │ process obtained within 3 months prior to          │
│ screening and evaluated by a qualified physician   │ screening and evaluated by a qualified physician   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous exposure to secukinumab or any other      │ Previous exposure to secukinumab or any other      │
│ biologic drug directly targeting Interleukin-17    │ biologic drug directly targeting Interleukin-17    │
│ (IL-17) Interleukin-12/23 (IL-12/23) or the IL-17  │ (IL-17) Interleukin-12/23 (IL-12/23) or the IL-17  │
│ receptor or any other biologic immunomodulating    │ receptor or any other biologic immunomodulating    │
│ agent except those targeting TNFa                  │ agent except those targeting TNFα                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have taken more than one anti-TNFa    │ Patients who have taken more than one anti-TNFα    │
│ agent                                              │ agent                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any intramuscular or intravenous corticosteroid    │ Any intramuscular or intravenous corticosteroid    │
│ injection within 2 weeks before baseline           │ injection within 2 weeks before baseline           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any therapy by intra-articular injections (e g     │ Any therapy by intra-articular injections (e g     │
│ corticosteroid) within 4 weeks before baseline     │ corticosteroid) within 4 weeks before baseline     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous treatment with any cell-depleting         │ Previous treatment with any cell-depleting         │
│ therapies                                          │ therapies                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients taking high potency opioid analgesics (e  │ Patients taking high potency opioid analgesics (e  │
│ g methadone hydromorphone morphine)                │ g methadone hydromorphone morphine)                │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                       │
╞═══════════════════════════════════════════════════════════════╡
│ Other protocol-defined inclusion/exclusion criteria may apply │
├───────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                             │
├───────────────────────────────────────────────────────────────┤
│ Key                                                           │
╘═══════════════════════════════════════════════════════════════╛